Download The Findit App

Share Your Posts On These Major Social Networks

Instatag Your Posts to Instagram Facebook + Twitter

News

MissionIR News - VistaGen Therapeutics (VSTA) Working to Revolutionize Depression Treatment

Atlanta 2/25/2015 8:00:00 PM

MissionIR would like to highlight VistaGen Therapeutics, Inc. (OTCQB: VSTA), a clinical-stage biopharmaceutical company focused on applying proprietary human pluripotent stem cell technology for drug rescue and cell therapy. Its Human Clinical Trials in a Test Tube is a pluripotent stem cell technology platform for predictive toxicology, drug development, and drug rescue.

In the company’s news:

VistaGen Therapeutics is currently collaborating with Dr. Carlos Zarate and the U.S. National Institutes Health (NIH) on an NIH-funded Phase 2 clinical study of its new drug candidate, AV-101, for the treatment of major depressive disorder (MDD).

Another drug, ketamine, has shown potential for treating patients suffering from MDD. Unfortunately, its prospects for widespread therapeutic use are limited because of its high potential for abuse, dissociative and psychosis-like side effects, and required intravenous administration in a medical center.

The industry is buzzing about AV-101, which is orally-active, because it may rapid-acting antidepressant benefits that are extremely similar to intravenous ketamine, without ketamine’s limiting side effects. “We are excited by the strong preclinical efficacy data supporting the ketamine-like antidepressant effects of AV-101, as well as the rapid and efficient oral-delivery and clinical safety range demonstrated by our successful Phase I clinical studies,” said H. Ralph Snodgrass, President and CSO of VistaGen. The company expects to complete its Phase 2 study by the end of this year.

While current MDD medications are part of a multi-billion dollar global antidepressant market, the available treatments have limited effectiveness in many cases. Although two out of three patients eventually find a drug combination that induces remission of their depression symptoms, the trial and error process that is presently in use is known to increase the risks of patient tolerability issues and serious side effects. Sadly, as many as 15 percent of individuals suffering with MDD commit suicide as a result.

AV-101’s mechanism of action is fundamentally different compared to current MDD medications. AV-101 works by modulating NMDA receptor channel activity by selectively binding to, and blocking, the glycine-binding co-agonist site of the NMDA receptor. By targeting the glycine-binding co-agonist site, the company’s drug candidate can bypass the adverse effects associated with ketamine without eliminating its surge of glutamate, which provides a powerful antidepressant effect to the patient. VistaGen’s AV-101 could prove to be the perfect solution to correct the flaws in the current treatment process.

MDD is a widespread and debilitating mental disorder affecting nearly 7 percent of U.S. adults. VistaGen, through its AV-101, could be on the brink of a breakthrough for MDD patients who do not benefit from existing antidepressants.

About MissionIR

MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.

To sign up for The MissionIR Report, please visit http://MissionIR.com

To connect with MissionIR via Facebook, please visit http://Facebook.com/MissionIR

To connect with MissionIR via Twitter, please visit http://Twitter.com/MissionIR

Please read FULL disclaimer on the MissionIR website: http://Disclaimer.MissionIR.com

Forward-Looking Statement:

This release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. Risks and uncertainties applicable to the company and its business could cause the company's actual results to differ materially from those indicated in any forward-looking statements.

More News

MissionIR News - International Stem Cell Corporation (ISCO) has a Place in the SAGE Encyclopedia of Stem Cell Research


Released On: 4/8/2016
Views: 3784

MissionIR News - eXp Realty International Corporation (EXPI) Attains Exclusive Rights to VirBELA Platform within Real Estate Industry


Released On: 4/7/2016
Views: 4530

MissionIR News - Moxian (MOXC): Social Media is a Necessity for Small Businesses Too


Released On: 3/31/2016
Views: 3502

MissionIR News - OurPet’s Company (OPCO) Reaches Favorable Settlement in Patent Infringement Case


Released On: 3/24/2016
Views: 2866

MissionIR News - Content Checked Holdings (CNCK) Reminds Us That You Are What You Eat


Released On: 3/17/2016
Views: 2414

MissionIR News - Oakridge Global Energy Solutions, Inc. (OGES) Promises Your Machine Will Start Every Time with its Lithium-Ion Battery


Released On: 3/11/2016
Views: 2236

MissionIR News - International Stem Cell Corp. (ISCO): Benefits of Stem Cells Outlined in Israel/California Collaboration


Released On: 3/4/2016
Views: 2556

MissionIR News - OurPet’s Company (OPCO) Adapting to a Constantly Changing Pet Products Industry with Innovation


Released On: 3/3/2016
Views: 2256

MissionIR News - Avoid Getting Poisoned with the Help of a Personal Food Taster from Content Checked Holdings (CNCK)


Released On: 2/23/2016
Views: 3603

MissionIR News - Oakridge Global Energy Solutions, Inc. (OGES) Ushering in a New Era in Battery Manufacturing


Released On: 2/12/2016
Views: 2588

MissionIR News - International Stem Cell Corp. (ISCO) Eyes Growth through Partnerships to Develop Therapeutic and Biomedical Products Worldwide


Released On: 2/10/2016
Views: 2306

MissionIR News - Torchlight Energy Resources, Inc. (TRCH) Moving Forward with Planning of Next Phase of Drilling on Orogrande Project


Released On: 2/9/2016
Views: 2457

MissionIR News - Content Checked Holdings, Inc. (CNCK) Updates Investors through Release of CEO’s Letter to Shareholders


Released On: 1/20/2016
Views: 4248

MissionIR News - International Stem Cell Corporation (ISCO) – Florey Clinical Service Agreement Expected to Deliver Results Later this Year


Released On: 1/14/2016
Views: 4711

MissionIR News - Moxian (MOXC) Announces Launch of New Subsidiary in Beijing


Released On: 1/5/2016
Views: 2960

MissionIR News - Elephant Talk Communications (ETAK) Initiates Restructuring of Global Business Operations with Executive and Board Appointments


Released On: 12/18/2015
Views: 9269

MissionIR News - International Stem Cell Corp. (ISCO) Has a Broad Pipeline of Targets


Released On: 12/9/2015
Views: 2712

MissionIR News - Oakridge Global Energy Solutions (OGES) is Flying High in the Drone Market


Released On: 12/3/2015
Views: 3153

Load More wait